Phase 3 N=3,871 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Breast Cancer
Primary: Relapse Free Survival (RFS) 4 vs. 6 Cycles — NA; NA years
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=711 Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Hyperlipidemia
Primary: Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12 — 1.0; -55.6 percent change — p=<0.001
Phase 3 N=1,560 Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Radiographic Progression-free Survival (rPFS) — 8.7; 13.8 months — p=<0.00001
Phase 3 N=462 A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
Hormone Receptor Positive Breast Cancer
Primary: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole — 16.6; 13.8 Months — p=0.0486
Phase 3 N=206 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks — -5.7; -6.35 units on a scale
Phase 3 N=646 Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia
Any Ear Nose or Throat Conditions · With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities
Primary: Immediate and Sustained Anesthetic Success for Cocaine HCl 4% Topical Solution and Placebo Topical Solution — 0.7093; 0.1969 proportion of participants — p=<0.0001
Phase 3 N=25 Study of Paliperidone ER in Adolescents and Young Adults With Autism
Autism
Primary: The Clinical Global Impression-Improvement(CGI-I) — 1.8 units on a scale
Phase 3 N=214 Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
Osteoporosis
Primary: Percent Change From Baseline to Month 12 in Lumbar Spine Areal Bone Mineral Density (aBMD) — 3.63; 0.14 percent change — p=<0.001
Phase 3 N=91 Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances
Acute Kidney Injury · Exercise-associated Hyponatremia · Perceived Exertion
Primary: Acute Kidney Injury — 16; 22 Participants
Phase 3 N=143 Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence
Smoking Cessation · Alcohol-Related Disorders
Primary: Smoking Abstinence — 19; 21; 12; 9 participants
Phase 3 N=24 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
Idiopathic Pulmonary Fibrosis · Cough
Primary: Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Cough Quality of Life Questionnaire. — 47.3; 55.2; 61.6; 44.5 units…
Phase 3 N=188 Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
Arthritis, Rheumatoid
Primary: Percentage of Participants With Positive Etanercept Anti-Drug Antibody (ADA) Status at Week 12 — 1.9 percentage of participants
Phase 3 N=1,314 An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Multiple Sclerosis, Relapsing-Remitting
Primary: Annualized Relapse Rate (ARR) — 0.19; 0.22; 0.16; 0.24 relapses per participant per year
Phase 3 N=46 Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery
Postoperative Pain
Primary: Pain Intensity — 6.29; 5.76; 5.51; 6.40 units on a scale
Phase 3 N=500 Adaptive Treatment for Alcohol and Cocaine Dependence
Substance Use Disorders
Primary: Treatment Engagement — 3.92; 3.50 treatment days — p=0.11